GSK343, the potent and selective inhibitor of EZH2, was recently discovered and reported to selectively reduce trimethylated H3K27 (H3K27me3) and inhibit breast cancer cell proliferation in cell-based studies21. This evidence concerns the gene EZH2 and breast carcinoma.